Emerging therapies for the treatment of ulcerative colitis

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756‐70.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.
   PubMed Web of Science ®Google Scholar
• Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterol. 2013;145:158–165.
   Web of Science ®Google Scholar
• Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–1635.
   Web of Science ®Google Scholar
• Peyrin–Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. 2014;12:929–934.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338.
   PubMed Web of Science ®Google Scholar
• Danese S, Roda G, Peyrin-Biroulet L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance. Nat Rev Gastroenterol Hepatol. 2020;17:1–2.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–353.
   PubMed Web of Science ®Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644–659.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel disease. Gastroenterol. 2017;152(2):351–361.e5.
   Web of Science ®Google Scholar
• Pagnini C, Arseneau KO, Cominelli F. Safety considerations when using anti-TNFalpha therapy to treat Crohn’s disease. Expert Opin Drug Saf. 2015;14:31–44.
   PubMed Web of Science ®Google Scholar
• Sokol H, Seksik P, Cosnes J. Complications and surgery in the inflammatory bowel diseases biological era. Curr Opin Gastroenterol. 2014;30:378–384.
   PubMed Web of Science ®Google Scholar
• Reinink AR, Lee TC, Higgins PDR. Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(8):1859–1869.
   PubMed Web of Science ®Google Scholar
• Flores BM, O’Connor A, Moss AC. Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis. Gastrointest Endosc. 2017 Dec;86(6):1006–1111.
   PubMed Web of Science ®Google Scholar
• Saxena AP, Limdi JK, Farraye FA. Zeroing in on endoscopic and histologic mucosal healing to reduce the risk of colorectal neoplasia in inflammatory bowel disease. Gastrointest Endosc. 2017 Dec;86(6):1112–1116.
   Web of Science ®Google Scholar
• Hanauer S, Panaccione R, Danese S, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019 Jan;17(1):139–147.
   PubMed Web of Science ®Google Scholar
• Isaacs KL. How rapidly should remission be achieved? Dig Dis. 2010;28(3):548–555.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zeng Z, Mukherjee A, et al. Molecular diagnosis and classification of inflammatory bowel disease. Expert Rev Mol Diagn. 2018;18(10):867–886.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(6):649–670.
   Web of Science ®Google Scholar
• de Mattos BRR, Garcia MPG, Nogueira JB, et al. Inflammatory bowel disease: an overview of immune mechanisms and biological treatments. Mediators Inflamm. 2015;2015:1–11.
   PubMedGoogle Scholar
• Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:601–616.
   PubMed Web of Science ®Google Scholar
• Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2003;(3):CD000543.
   PubMed Web of Science ®Google Scholar
• Ford AC, Khan KJ, Achkar JP, et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:167–176.
   PubMed Web of Science ®Google Scholar
• Sehgal P, Colombel J‐F, Aboubakr A, et al. Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther. 2018;47:1597–1609.
   PubMed Web of Science ®Google Scholar
• Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012;5(2):113–123.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D. et al.The European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohn’s Colitis. 2017 July;11(7):769–784.
   Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Gastroenterol. 2011;6(4):644–659.
   Google Scholar
• Troncone E, Monteleone G. The safety of non-biological treatments in ulcerative colitis. Expert Opin Drug Saf. 2017;16(7):779–789.
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterol. 2001;121(2):255–260.
   PubMed Web of Science ®Google Scholar
• Timmer A, Patton PH, Chande N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;(5):CD000478.
   Web of Science ®Google Scholar
• Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–523.
   PubMed Web of Science ®Google Scholar
• Rayner CK, McCormack G, Emmanuel AV, et al. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2003;18(3):303–308.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553–1563.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Cheifetz AS. Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF therapy. Am J Gastroenterol. 2017;112(5):673–676.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352(24):2499–2507.
   PubMed Web of Science ®Google Scholar
• Bickston SJ, Behm BW, Tsoulis DJ, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014;(8):CD007571.
   PubMed Web of Science ®Google Scholar
• Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nat. 2012;491:119–124.
   Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–1736.
   PubMed Web of Science ®Google Scholar
• Cohen R, Yu A, Wu E, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31:693–707.
   PubMed Web of Science ®Google Scholar
• Limsrivilai J, Stidham RW, Govani SM, et al. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017;15:385–392.
   PubMed Web of Science ®Google Scholar
• Rao BB, Click BH, Koutroubakis IE, et al. The cost of Crohn’s disease: varied health care expenditure patterns across distinct disease trajectories. Inflamm Bowel Dis. 2017;23:107–115.
   PubMed Web of Science ®Google Scholar
• Yu H, MacIsaac D, Wong JJ, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2018;47:364–370.
   PubMed Web of Science ®Google Scholar
• Park KT, Ehrlich OG, Allen JI, et al. The cost of inflammatory bowel disease: an initiative from the Crohn’s & Colitis Foundation. Inflammatory Bowel Diseases. 2020;26(1):1–10.
   PubMed Web of Science ®Google Scholar
• Parkin J, Cohen B. An overview of the immune system. Lancet. 2001;357:1777–1789.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Li Y, Johansson-Lindbom B, et al. Sphingosine1-phosphate signaling in inflammatory bowel disease. Trends Mol Med. 2017;23:362–374.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278:1910–1914.
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116:1218–1222.
   PubMed Web of Science ®Google Scholar
• Gaffen SL, Jain R, Garg AV, et al. The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585–600.
   PubMed Web of Science ®Google Scholar
• Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16:185–196.
   PubMed Web of Science ®Google Scholar
• Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006;203(11):2473–2483.
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167:668–677.
   PubMed Web of Science ®Google Scholar
• Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurother. 2017;14:859–873.
   PubMed Web of Science ®Google Scholar
• Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366:339–347.
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare products Regulatory Agency. Fingolimod (Gilenya): risks of progressive multifocal leukoencephalopathy, basal-cell carcinoma, and opportunistic infections. 2016.
   Google Scholar
• Cohen JA, Arnold DL, Comi G, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:373–381.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374:1754–1762.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Trokan L, Zhang J, et al. A randomized, double-blind, placebo controlled trial of a selective, oral sphingosine 1-phosphate receptor modulator, Etrasimod (APD334), in moderate to severe ulcerative colitis: results from the OASIS study. s.l.: Paper presented at United European Gastroenterology Week; 2018; Vienna, Austria.
   Google Scholar
• Peyrin-Biroulet L, Panés J, Chiorean MV, et al. Histologic remission and mucosal healing in a randomized, placebo-controlled, Phase 2 study of Etrasimod in patients with moderately to severely active ulcerative colitis. Gastroenterol. 2019;156(6):S-217.
   Google Scholar
• Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of Mirikizumab in a randomized Phase 2 study of patients with ulcerative colitis. Gastroenterol. 2020;158(3):537–549.
   Google Scholar
• Sandborn WJ, Ferrante M, Bhandari BR, et al. Extended treatment with mirikizumab in patients with moderately-to-severely active ulcerative colitis: results from a phase 2 trial. Gastroenterol. 2019;156:S1094.
   Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389:1699–1709.
   PubMed Web of Science ®Google Scholar
• Stefanich EG, Danilenko DM, Wang H, et al. A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol. 2011 Apr;162(8):1855–1870.
   PubMed Web of Science ®Google Scholar
• Farstad IN, Halstensen TS, Lien B, et al. Distribution of beta 7 integrins in human intestinal mucosa and organized gut-associated lymphoid tissue. Immunol. 1996;89:227–237.
   PubMed Web of Science ®Google Scholar
• Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384:309–318.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Sandborn WJ, Danese S, et al. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:135–144.
   PubMedGoogle Scholar
• Reinisch W, Sandborn WJ, Danese S, et al. P036 long-term safety and efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: an open-label extension study (TURANDOT II). Inflamm Bowel Dis. 2019;25:S18–S18.
   Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Danese S, et al. DOP51 Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis. J Crohn’s Colitis. 2019;13:S058– S059.
   Google Scholar
• Reinisch W, Sandborn WJ, Danese S, et al. DOP49 Efficacy of the antimucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II. J Crohn’s Colitis. 13.
   Google Scholar
• Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54:859–874.
   PubMed Web of Science ®Google Scholar
• Hemperly A, Sandborn WJ, Vande Casteele N. Clinical pharmacology in adult and pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:2527–2542.
   PubMed Web of Science ®Google Scholar
• Soendergaard C, Bergenheim FH, Bjerrum JT, et al. Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther. 2018;192:100–111.
   PubMed Web of Science ®Google Scholar
• Sabino J, Verstockt B, Vermeire S, et al. New biologics and small molecules in inflammatory bowel disease: an update. Ther Adv Gastroenterol. 2019;12:1–14.
   Web of Science ®Google Scholar
• Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291–1302.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85–95.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Motoya S, Hanai H, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49:283–294.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265.
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019 Sep 26;381:1215–1226.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Al‐Taweel T, Yaghoobi M, et al. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn’s disease: a systematic review and meta‐analysis. J Crohns Colitis. 2014;8:1632–1641.
   PubMed Web of Science ®Google Scholar
• Verstockt B, Verstockt S, Creyns B, et al. Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn’s disease. Aliment Pharmacol Ther. 2018;49:572–581.
   Web of Science ®Google Scholar
• Gaujoux R, Starosvetsky E, Maimon N, et al. Cell-centred meta-analysis reveals baseline predictors of anti-TNFalpha non-response in biopsy and blood of patients with IBD. Gut. 2019;68:604–614.
   PubMed Web of Science ®Google Scholar
• Stallmach A, Langbein C, Atreya R, et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Aliment Pharmacol Ther. 2016;44:1199–1212.
   PubMed Web of Science ®Google Scholar
• Narula N, Peerani F, Meserve J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018;113:1345.
   PubMed Web of Science ®Google Scholar
• Danese S. Ulcerative colitis: a cinderella story. Curr Drug Targets. 2011;12:1372.
   PubMed Web of Science ®Google Scholar
• Weisshof R, El Jurdi K, Zmeter N, et al. Emerging therapies for inflammatory bowel disease. Adv Ther. 2018;35(11):1746–1762.
   PubMed Web of Science ®Google Scholar
• Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66:199.
   PubMed Web of Science ®Google Scholar